Unlocking the opportunity of tight glycaemic control: Inhaled insulin: Safety

Diabetes, Obesity and Metabolism

Volumn 7, Issue SUPPL.1, 2005, Pages

  Brain, Joseph D ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Diabetes; Inhaled insulin; Insulin safety; Pulmonary function; Respiratory adverse events

Indexed keywords

ANTIDIABETIC AGENT; INSULIN;

ANIMAL; BREATHING MECHANICS; CHEMICALLY INDUCED DISORDER; COUGHING; DIABETES MELLITUS; DRUG EFFECT; HUMAN; INHALATIONAL DRUG ADMINISTRATION; REVIEW;

ADMINISTRATION, INHALATION; ANIMALS; COUGH; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; RESPIRATORY MECHANICS;

EID: 33644838963     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2005.00527.x     Document Type: Review

References (27)

1. Cefalu WT. Concept, strategies, and feasibility of noninvasive insulin delivery. Diabetes Care 2004; 27: 239-246.
2. Patton JS, Bukar J, Nagarajan S. Inhaled insulin. Adv Drug Deliv Rev 1999; 35: 235-247.
3. Patton JS. Mechanisms of macromolecule absorption by the lungs. Adv Drug Deliv Rev 1996; 19: 3-36.
4. Newhouse MT. Tennis anyone? The lungs as a new court for systemic therapy. CMAJ 1999; 161: 1287-1288.
5. Data on file. New York, NY: Pfizer, 2005.
6. Finch GL. In: Salem H, Katz SA eds. Inhalation Toxicology, 2nd edition. Boca Raton, FL: CRC Press, 2005.
7. Schatz H. Inhaled insulin and the dream of a needle-free insulin application. Exp Clin Endocrinol Diabetes 2004; 112: 285-287.
8. Heinemann L, Traut T, Heise T. Time-action profile of inhaled insulin. Diabet Med 1997; 14: 63-72.
9. Köhler D, Schluter KJ, Kerp L et al. Nicht radioaktives verfahren zur messung der lungenpermeabilitat: Inhalation von insulin. Atemw Lugenkr 1987; 13: 230-232.
10. Laube BL, Georgopoulos A, Adams GK III. Preliminary study of the efficacy of insulin aerosol delivered by oral inhalation in diabetic patients. JAMA 1993; 269: 2106-2109.
11. Jendle JH, Karlberg BE. Effects of intrapulmonary insulin in patients with non-insulin-dependent diabetes. Scand J Clin Lab Invest 1996; 56: 555-561.
12. Jendle JH, Karlberg BE. Intrapulmonary administration of insulin to healthy volunteers. J Intern Med 1996; 240: 93-98.
13. Quattrin T, Belanger A, Bohannon NJ et al. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 2004; 27: 2622-2627.
14. Skyler JS, Weinstock RS, Raskin P et al. Use of inhaled insulin in a basal/bolus insulin regimen in subjects with type 1 diabetes: A 6-month, randomized, comparative trial. Diabetes Care 2005; 28: 1630-1635.
15. Zwickl CM, Smith HW, Zimmermann JL et al. Immunogenicity of biosynthetic human LysPro insulin compared to native-sequence human and purified porcine insulins in rhesus monkeys immunized over a 6-week period. Arzneimittelforschung 1995; 45: 524-528.
16. ® Prescribing Information.http://www.gene.com/gene/products/information/opportunistic/pulmozyme/insert.jsp
17. Ganong WF. Review of Medical Physiology. Stamford, CT: Appleton & Lange, 1999.
18. Rossi A, Ganassini A, Tantucci C et al. Aging and the respiratory system. Aging (Milano) 1996; 8: 143-161.
19. Koenig SM. Pulmonary complications of obesity. Am J Med Sci 2001; 321: 249-279.
20. Hsia CC, Raskin P. The diabetic lung: relevance of alveolar microangiopathy for the use of inhaled insulin. Am J Med 2005; 118: 205-211.
21. Himmelmann A, Jendle J, Mellen A et al. The impact of smoking on inhaled insulin. Diabetes Care 2003; 26: 677-682.
22. Henry RR, Mudaliar SR, Howland WC III et al. Inhaled insulin using the AERx Insulin Diabetes Management System in healthy and asthmatic subjects. Diabetes Care 2003; 26: 764-769.
23. Barnett A for the Exubera Phase 3 Study Group. Efficacy and one-year pulmonary safety of inhaled insulin (Exubera) as adjunctive therapy with metformin or glibenclamide in type 2 diabetes patients poorly controlled on oral agent monotherapy. Diabetes 2004; 53 (Suppl. 2):A107.
24. Dreyer M for the Exubera Phase 3 Study Group. Efficacy and 2-year pulmonary safety data of inhaled insulin as adjunctive therapy with metformin or glibenclamide in type 2 diabetes patients poorly controlled with oral monotherapy. Diabetologia 2004; 47 (Suppl. 1):A44.
25. ®) improves glycaemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized controlled trial. Annals Intern Med (in press).
26. Skyler JS for the Exubera Phase 3 Study Group. Long-term, sustained efficacy, and safety of inhaled insulin after 4 years of continuous therapy. Diabetologia 2004; 47 (Suppl. 1):A311.
27. Hollander PA, Blonde L, Rowe R et al. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 2004; 27: 2356-2362.